SCHEMBL26720686

SCHEMBL26720686

O=c1cc(-c2ccccc2OCc2ccc(F)cc2)[nH]c2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSV O60911 6/20 0.59
CTSL P07711 6/20 0.59
LMNA P02545 6/20 0.50
HPGD P15428 6/20 0.50
KDM4E B2RXH2 3/20 0.47
TUBB4A P04350 1/20 0.47
TP53 P04637 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47
TUBA4A P68366 1/20 0.47
TUBB4B P68371 1/20 0.47
TUBB3 Q13509 1/20 0.47
TUBB2A Q13885 1/20 0.47
TUBB8 Q3ZCM7 1/20 0.47
TUBA3E Q6PEY2 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TUBA1A Q71U36 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TUBA1C Q9BQE3 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26685280 0.91 CTSV (0.54) CTSVCTSLLMNAHPGDKDM4E
SCHEMBL26720404 0.91 LMNA (0.55) CTSVCTSLLMNAHPGDKDM4E
SCHEMBL26865915 0.78 CTSV (0.53) CTSVCTSLLMNAHPGDKDM4E
SCHEMBL26720683 0.78 HTR2C (0.49) CTSVCTSLLMNAHPGDKDM4E
SCHEMBL26685230 0.78 PDE5A (0.48) CTSVCTSLLMNAHPGDKDM4E
SCHEMBL26847033 0.77 HPGD (0.63) CTSVCTSLLMNAHPGDKDM4E
SCHEMBL341333 0.77 SRD5A2 (0.44) CTSVCTSLLMNAHPGDKDM4E
SCHEMBL26723109 0.76 CTSV (0.54) CTSVCTSLLMNAHPGDKDM4E
SCHEMBL29411879 0.75 CTSV (1.00) CTSVCTSLLMNAHPGDKDM4E
SCHEMBL6001399 0.75 CTSV (1.00) CTSVCTSLLMNAHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373925-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-23 US disclosed
US-20230373925-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-23 US disclosed
WO-2023205463-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373925-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN TRPV1, SCN3A, KCNN3 CTSV 2242/4885CTSL 3079/4885LMNA 3454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.